OTC · FPMI
FluoroPharma Medical, Inc.
$0.00$0.00 (0.0%)
FluoroPharma Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · GBIM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GlobeImmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow GlobeImmune, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
FluoroPharma Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Rebus Holdings, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Sienna Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Comera Life Sciences Holdings, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Synovics Pharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Imagenetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Neurobiological Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Anthera Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
